EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

EKF announces that results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.

Study using PointMan DNA enrichment technology have been accepted for publication in Clinical Cancer Research.

EKF announces that it is exhibiting its range of Maternal and Women's Health products at the XXI FIGO World Congress - the International Federation of Gynecology and Obstetrics - in Vancouver, Canada, 4-9th October.

28th Sep 2015

EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2015.

Studies confirm utility of PointMan for molecular analysis of CTCs and circulating DNA in liquid biopsies

EKF Diagnostics announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham, UK, 28-30 September. 

EKF announces that two research posters supporting its PointMan™ molecular diagnostic technology have been delivered at key conferences.